LEXICON PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Lexicon Pharmaceuticals, Inc. | |||
| Date: | March 5, 2026 | By: | /s/ MICHAEL S. EXTON |
|---|---|---|---|
| Michael S. Exton, Ph.D. | |||
| Chief Executive Officer | |||
| Date: | March 5, 2026 | By: | /s/ SCOTT M. COIANTE |
| Scott M. Coiante | |||
| Senior Vice President and Chief Financial Officer | |||
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael S. Exton, Ph.D. and Scott M. Coiante, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ MICHAEL S. EXTON | Chief Executive Officer and Director(Principal Executive Officer) | March 5, 2026 |
| Michael S. Exton, Ph.D. | ||
| /s/ SCOTT M. COIANTE | Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | March 5, 2026 |
| Scott M. Coiante | ||
| /s/ RAYMOND DEBBANE | Chairman of the Board of Directors | March 5, 2026 |
| Raymond Debbane | ||
| /s/ PHILIPPE J. AMOUYAL | Director | March 5, 2026 |
| Philippe J. Amouyal | ||
| /s/ SAMUEL L. BARKER | Director | March 5, 2026 |
| Samuel L. Barker, Ph.D. | ||
| /s/ IVAN H. CHEUNG | Director | March 5, 2026 |
| Ivan H. Cheung | ||
| /s/ CHRISTOPHER J. SOBECKI | Director | March 5, 2026 |
| Christopher J. Sobecki | ||
| /s/ DIANE E. SULLIVAN | Director | March 5, 2026 |
| Diane E. Sullivan | ||
| /s/ JUDITH L. SWAIN | Director | March 5, 2026 |
| Judith L. Swain, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.